Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05451004 · ClinicalTrials.gov registry record · Phase 3

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

A Phase 3 study of Oropharyngeal Cancer, sponsored by Canadian Cancer Trials Group.

Recruiting
Registry status
Phase 3
Development phase
510
Enrollment target
20
Study locations

NCT05451004 is a Phase 3 study of Oropharyngeal Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 510 participants, above the 169-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (202% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05451004, a Phase 3 study of Oropharyngeal Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.

RECRUITING
Registry status
Phase 3
Development phase
510 participants
Enrollment target
20
Study locations

Study Summary

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?

Conditions Studied

Oropharyngeal Cancer

Interventions

  • OTHER Lymphatic Mapping with SPECT-CT
  • RADIATION Ipsilateral and Contralateral Neck

Study Locations (20)

Florida

  • UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
  • Baptist MD Anderson Cancer Center - Jacksonville
  • University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
  • Moffitt Cancer Center-International Plaza - Tampa
  • Moffitt Cancer Center - McKinley Campus - Tampa
  • Moffitt Cancer Center - Tampa

Michigan

  • University of Michigan Rogel Cancer Center - Ann Arbor
  • University of Michigan - Brighton Center for Specialty Care - Brighton
  • Henry Ford Hospital - Detroit

California

  • City of Hope Corona - Corona
  • City of Hope Comprehensive Cancer Center - Duarte

Illinois

  • Northwestern University - Chicago
  • Northwestern Medicine Cancer Center Warrenville - Warrenville

Texas

  • MD Anderson in The Woodlands - Conroe
  • M D Anderson Cancer Center - Houston

Georgia

  • Emory University Hospital Midtown - Atlanta

Kentucky

  • The James Graham Brown Cancer Center at University of Louisville - Louisville

Missouri

  • MU Health - University Hospital/Ellis Fischel Cancer Center - Columbia

Trial Details

FieldValue
Enrollment Target 510 participants
Start Date 2023-02-10
Est. Completion 2031-08-30
Phase Phase 3

Sponsor

Canadian Cancer Trials Group

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05451004

The ClinicalTrials.gov registry entry for NCT05451004 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 169-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (202% higher). The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Oropharyngeal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Lymphatic Mapping with SPECT-CT is the first listed.

NCT05451004 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Michigan, California.

Frequently Asked Questions

What is clinical trial NCT05451004 about?

NCT05451004 is a clinical study titled "SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer". This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to...

What is the current status of trial NCT05451004?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2023-02-10. Estimated completion is 2031-08-30.

What conditions does trial NCT05451004 study?

This clinical trial studies the following conditions: Oropharyngeal Cancer.

What interventions are being tested in trial NCT05451004?

The interventions under investigation include: Lymphatic Mapping with SPECT-CT (OTHER), Ipsilateral and Contralateral Neck (RADIATION).

Who is sponsoring clinical trial NCT05451004?

This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05451004 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Oropharyngeal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Oropharyngeal Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.